Wedbush Issues Pessimistic Forecast for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Analysts at Wedbush lowered their Q3 2025 EPS estimates for shares of Adherex Technologies in a research note issued on Monday, October 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.06) for the quarter, down from their previous estimate of $0.40. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Adherex Technologies’ Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $0.68 EPS and FY2028 earnings at $1.55 EPS.

Adherex Technologies (NASDAQ:FENC) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $9.76 million for the quarter, compared to analysts’ expectations of $9.52 million.

FENC has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday, August 21st. Craig Hallum lifted their price objective on shares of Adherex Technologies from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Zacks Research lowered shares of Adherex Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Adherex Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adherex Technologies currently has an average rating of “Moderate Buy” and an average price target of $13.33.

Adherex Technologies Stock Up 5.9%

NASDAQ:FENC opened at $8.76 on Wednesday. The company has a fifty day moving average of $8.83 and a 200-day moving average of $7.82. The firm has a market capitalization of $244.50 million, a P/E ratio of -20.86 and a beta of 0.64. Adherex Technologies has a twelve month low of $3.96 and a twelve month high of $9.92.

Institutional Investors Weigh In On Adherex Technologies

Several institutional investors have recently added to or reduced their stakes in FENC. AIGH Capital Management LLC purchased a new stake in Adherex Technologies during the first quarter valued at about $2,199,000. Nuveen LLC purchased a new stake in Adherex Technologies during the first quarter valued at about $158,000. AQR Capital Management LLC bought a new stake in shares of Adherex Technologies during the first quarter valued at about $66,000. Finally, Jane Street Group LLC bought a new stake in shares of Adherex Technologies during the first quarter valued at about $90,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Adherex Technologies

In related news, major shareholder Southpoint Capital Advisors Lp sold 26,900 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $9.59, for a total value of $257,971.00. Following the transaction, the insider directly owned 4,050,314 shares of the company’s stock, valued at approximately $38,842,511.26. The trade was a 0.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $9.78, for a total transaction of $97,800.00. Following the sale, the director directly owned 82,501 shares in the company, valued at approximately $806,859.78. This trade represents a 10.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,889 shares of company stock worth $831,426 over the last three months. 11.76% of the stock is owned by insiders.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.